Skip to main content
Premium Trial:

Request an Annual Quote

Castle Bio Licenses IP from Brigham and Women's Hospital for Mesothelioma Test

NEW YORK (GenomeWeb News) – Castle Biosciences has licensed the IP and technology rights from Brigham and Women's Hospital for a gene expression profiling test for mesothelioma, the company announced today.

Called DecisionDx-Mesothelioma, the test was developed and validated by the hospital and confirms differential diagnosis and predicts survival in patients undergoing standard of care surgical resection, the Friendswood, Texas-based firm said. Castle Bio added that it is completing validation of the test under College of American Pathologists accredited and CLIA-certified standard operating procedures.

The company is targeting the fourth quarter for a launch of the test.

Financial and other terms of the deal were not disclosed.

"We now have a molecular test that alone as well as in conjunction with other simple clinical parameters can help identify those patients who will most likely benefit from aggressive surgery, as well as assist with fundamental treatment planning," said Raphael Bueno, associate chief of thoracic surgery at Brigham and Women's Hospital and a professor of surgery at Harvard Medical School, who led the team in developing the test.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.